Press release
Endometriosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Endometriosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Endometriosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Endometriosis Pipeline Report
* In January 2025:- Organon and Co .- The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
* In January 2025:- AbbVie - A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain.
* DelveInsight's Endometriosis pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Endometriosis treatment.
* The leading Endometriosis Companies such as ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
* Promising Endometriosis Therapies such as Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
Discover how the endometriosis treatment paradigm is evolving. Access DelveInsight's in-depth Endometriosis Pipeline Analysis for a closer look at promising breakthroughs @ Endometriosis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Endometriosis Emerging Drugs Profile
* Linzagolix: ObsEva
ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression.
* HMI-115: Hope Medicine (Nanjing) Co., Ltd
HMI-115 is a first-in-class monoclonal antibody drug that Hope Medicine owns the global rights. In April 2019, Hope Medicine and Bayer AG signed an exclusive global license agreement for the development and commercialization of HMI-115, a monoclonal antibody targeting the prolactin receptor (PRLR), for multiple indications globally. Potential indications for the antibody include Endometriosis (EM), Androgenic Alopecia (AGA), and other chronic diseases. In 2021, Hope Medicine received approval from the FDA and EMA to conduct MRCT Phase II clinical trials for the treatment of endometriosis Hope Medicine has now completed patient enrollment and dosing at all clinical trial centers in the US and Europe.
* VAL-301: ValiRx
VAL-301 is a small molecule, peptide, and new chemical entity it is developed in-house by ValiRx, under evaluation by an undisclosed Japanese Pharmaceutical Company. VAL301 peptide re-purposed towards non-cancerous cell proliferation. The mechanism of action of drug candidate is inhibition of androgen activation of SRC kinase. Currently, the drug is in preclinical stage of its development for the treatment of endometriosis.
Get a detailed analysis of the latest innovations in the endometriosis pipeline. Explore DelveInsight's expert-driven report today! @ Endometriosis Unmet Needs [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Endometriosis Companies
ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Endometriosis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Endometriosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Endometriosis Pipeline Report
* Coverage- Global
* Endometriosis Companies- ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
* Endometriosis Therapies- Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
* Endometriosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Endometriosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in endometriosis drug development? Find out in DelveInsight's exclusive Endometriosis Pipeline Report-access it now! @ Endometriosis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Endometriosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Endometriosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Linzagolix: ObsEva
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HMI-115: Hope Medicine (Nanjing) Co., Ltd
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* VAL-301: ValiRx
* Drug profiles in the detailed report.....
* Inactive Products
* Endometriosis Key Companies
* Endometriosis Key Products
* Endometriosis- Unmet Needs
* Endometriosis- Market Drivers and Barriers
* Endometriosis- Future Perspectives and Conclusion
* Endometriosis Analyst Views
* Endometriosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometriosis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3855000 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Endometriosis
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.01 billion In 2028 At A…
Endometriosis Market Trends, Size, Forecast - 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and…
Global Endometriosis Market Research and Forecast 2018-2023
Global endometriosis market size, share, market trends, research and analysis report by diagnosis (ultrasound, pelvic exam, laparoscopy, MRI, hysteroscopy, son hysterography) by treatment (hormonal therapy, pain management) forecast 2018-2023
According to the OMR analysis, the global endometriosis market is growing at a significant rate during 2018-2023. The global endometriosis market has been growing significantly due availability of enhanced medications for the disease. The global endometriosis market is segmented on the basis…
